#USA #New York #Pomerantz Law Firm #Syndax Pharmaceuticals #Investor Claims

Pomerantz Law Firm Launches Investigation into Syndax Pharmaceuticals

The Pomerantz Law Firm, a notable name in the realm of corporate litigation, is currently scrutinizing practices pertaining to Syndax Pharmaceuticals, Inc., a company listed on NASDAQ under the ticker symbol SNDX. As part of their investigation, Pomerantz aims to determine whether Syndax, in conjunction with some of its officers or directors, has participated in unethical business practices or engaged in securities fraud that could affect investors.

In a recent press release dated October 12, 2026, Syndax disclosed vital information regarding their MAXPIRe Phase 2 trial involving axatilimab for treating idiopathic pulmonary fibrosis (IPF). The company reported that the trial did not achieve its primary endpoint, which focused on measuring the annualized rate of decline in forced vital capacity (FVC). This disappointing announcement prompted a significant drop in Syndax's stock price, which fell by $0.44, equating to a 2.59% decline, ultimately closing at $16.55 per share on the same day.

Pomerantz LLP, with offices spread across major cities including New York, Chicago, Los Angeles, and even international locations like London and Paris, has a long-standing reputation for championing the rights of individuals who may have suffered due to corporate misconduct or securities fraud. The firm was founded by Abraham L. Pomerantz, often referred to as the dean of the class action bar due to his foundational work in the field. For over 85 years, Pomerantz has continued its mission to advocate for investors, recovering significant damages on behalf of class members affected by breaches of fiduciary duty and wrongful business practices.

The firm encourages any investors of Syndax Pharmaceuticals to reach out for assistance, especially if they suspect they may have been impacted by the company's recent activities or announcements. Danielle Peyton, a representative from Pomerantz, is on hand to handle inquiries and can be contacted directly via phone at 646-581-9980, ext. 7980, or through email at [email protected].

Pomerantz’s commitment to investor protection underscores the firm's dedication to ensuring that justice is served in the world of finance, where unethical practices can lead to significant financial losses for unsuspecting stakeholders. As this investigation unfolds, all eyes will be on Syndax Pharmaceuticals and their response to these serious allegations.

In conclusion, investors should stay vigilant about developments regarding Syndax and may wish to consider their options moving forward. Participation in class action lawsuits can often provide a pathway for recourse against larger corporate entities, highlighting the importance of legal representation when navigating potential securities fraud issues. With Pomerantz Law Firm's extensive expertise and historical success in such cases, they stand ready to guide affected investors through this challenging scenario, reinforcing their position as a leader in investor protection in the legal landscape.